Stockwinners Market Radar for February 24, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

17:19 EST SAIC awarded $102.48M Navy contract modification - SAIC was awarded a $102.48M firm-fixed-price and cost-plus-fixed fee modification to previously awarded contract to exercise options for the production, spares, production support material, engineering support and hardware repair of components for MK 48 Heavyweight Torpedo All Up Round. This modification is in support of the MK 48 Mod 7 Heavyweight Torpedo program. This contract combines purchases to support the Navy, the Royal Australian Navy, and the government of Taiwan under the Foreign Military Sales, or FMS, program. Work is expected to be completed by January 2026. FY22 weapons procurement in the amount of $29.9M and FY23 weapons procurement in the amount of $26.3M will be obligated at time of award and will not expire at the end of the current fiscal year. Naval Sea Systems Command is the contracting activity.

16:51 EST Vaalco Energy receives exceptive relief from Canadian securities authorities - Vaalco Energy announced that it has received exceptive relief from the applicable Canadian securities authorities regarding future filing requirements. Vaalco became a reporting issuer in each of the provinces of Canada by virtue of its business combination with TransGlobe in October 2022, which made it subject to Canadian continuous disclosure and other reporting obligations under applicable Canadian securities laws.

16:18 EST PayPal urges stockholders reject mini-tender offer by TRC Capital - PayPal has been notified of an unsolicited mini-tender offer by TRC Capital to purchase up to up to 2M shares of PayPal common stock, representing significantly less than one percent of PayPal's common stock outstanding. The offering price of $71.36 per share is 4.42% below the closing price per share of PayPal's common stock on February 17. PayPal recommends that stockholders do not tender their shares in response to TRC's offer because the offer is below the current market price of PayPal's shares and is subject to numerous conditions, including TRC Capital obtaining financing for the offer. There is no guarantee the conditions of the offer will be satisfied. Stockholders who have already tendered their shares may withdraw them at any time by providing notice in the manner described in the TRC offering documents prior to the expiration of the offer, which is currently scheduled for 12:01 a.m. EDT on March 22, unless extended. PayPal does not endorse TRC unsolicited mini-tender offer and is not affiliated or associated in any way with TRC, its mini-tender offer, or its mini-tender offer documents.

16:16 EST Regional Health Properties regains compliance with NYSE American standards - Regional Health Properties announced that the company received a notice from the NYSE American LLC on February 21, 2023 that the Company has regained compliance with the continued listing standard set forth in Section 704 of the NYSE American Company Guide. Specifically, the company has resolved the continued listing deficiency with respect to its failure to hold an annual meeting of shareholders for the fiscal year ended December 31, 2021.

16:05 EST Neptune Wellness announces receipt of Nasdaq notification - Neptune Wellness Solutions announced that the company has received written notification from the Listing Qualification Department of the Nasdaq Stock Market LLC on February 23, 2023, notifying the Company that it is no longer in compliance with Nasdaq Listing Rule 5250(c)(1), as a result of Neptune not having timely filed its Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2022 with the U.S. Securities and Exchange Commission.

15:41 EST Norfolk Southern announces paid sick leave agreement with Mechanical railroaders - Norfolk Southern announced that it has reached an agreement with another one of its labor unions to provide their members the ability to take up to seven paid sick days per year. The new paid sick leave benefit will provide these employees four new days of paid sick leave while also offering them the ability to more flexibly use three additional days of existing paid time off as sick leave. This agreement was reached in collaboration with the National Conference of Firemen and Oilers and is available immediately to approximately 200 Mechanical railroaders. The announcement follows Wednesday's agreement reached with the Brotherhood of Maintenance of Way Employees to extend paid sick days to 3,000 Engineering craft railroaders who work for Norfolk Southern. These announcements come on the heels of last year's agreement reached during national bargaining to provide historic wage increases and premium health care benefits to union employees.

15:15 EST Decarbonization Plus Acqustn Corpn IV trading resumes

15:08 EST Range Resources higher, Pioneer Natural lower after report on possible tie-up - Shares of two energy names are moving in opposite directions this afternoon after Bloomberg reported that Pioneer Natural Resources (PXD) is considering an acquisition of Range Resources (RRC), citing people familiar with the matter. Pioneer Natural is seeking further consolidation in the shale industry, sources told Bloomberg's Ed Hammond and Dinesh Nair. Deliberations are ongoing and there's no certainty the companies will reach an agreement, the peopled added. Shares of Range Resources are up $3.08, or 12%, to $28.34 in Friday afternoon trading following the report, while Pioneer Natural has fallen $10.40, or 5%, to $194.66. Reference Link

14:52 EST Range Resources trading resumes

14:47 EST Range Resources trading halted, volatility trading pause

13:03 EST Macy's increases quarterly dividend 5% - The board of Macy's declared a regular quarterly dividend of 16.54c per share on Macy's common stock, an increase of 5%, payable April 3 to shareholders of record at the close of business on March 15.

12:54 EST Cvent down 3% to $7.40 after Reuters report of rejected Blackstone bid

12:24 EST Creatd terminates discussions with Global Tech on proposed acquisition - Creatd (CRTD) has decided not to proceed with a proposed transaction with Global Tech Industries Group, Inc. (GTII). While Creatd has concluded discussions of a proposed acquisition, it will honor the no-shop terms outlined in the Letter of Intent signed with GTII.

12:00 EST Ambrx Biopharma falls -23.4% - Ambrx Biopharma is down -23.4%, or -$1.53 to $5.00.

12:00 EST Zeta Global rises 12.4% - Zeta Global is up 12.4%, or $1.12 to $10.18.

12:00 EST Universal Insurance rises 15.0% - Universal Insurance is up 15.0%, or $1.87 to $14.37.

11:24 EST Century Aluminum supports Biden administration tariffs on Russian aluminum - Century Aluminum Company released the following statement from President and CEO Jesse Gary in support of the Biden administration's decision to implement a 200% tariff on Russian aluminum imports into the United States: "Century Aluminum fully supports the Biden administration's decision to impose significant tariffs on the import of Russian aluminum and Russian aluminum embedded in downstream articles. For too long, Russian aluminum producers have flooded the market with excess production, undercutting U.S. competitors without consequence. A thriving domestic aluminum market is essential to today's U.S. national security, economic, and climate objectives. These tariffs make our country safer, more economically independent, and more sustainable, and will strengthen our domestic supply chain, make the U.S. less reliant on those who wish us harm, and put our country on a steadier path to a green future."

11:09 EST Medtronic announces one-year data from ADAPT study of MiniMed 780G system - Medtronic announced one-year data from the ADAPT study, the first multi-national randomized controlled study comparing the performance of the MiniMed 780G advanced hybrid closed loop system against multiple daily injections of insulin with an intermittently scanned CGM. The study was done in adults not meeting glycemic targets. The initial 6-month results, published in The Lancet Diabetes & Endocrinology, showed AHCL system users experienced a 27.6% absolute increase in Time in Range and 1.4% reduction in HbA1C compared to those on MDI + isCGM without increased time in hypoglycemia. These results were even greater overnight with a TIR increase of 30.2%. At the close of the 6-month study period, all participants on MDI + isCGM crossed over to the MiniMed 780G system. At one year, these significant improvements were reproduced in this cross-over group and sustained in those that started on AHCL therapy at the start of the trial. These latest results were presented today at the 2023 Advanced Technologies & Treatments for DiabetesConference in Berlin. Data from a second randomized controlled study sponsored by JDRF, called the CLVer Trial, showed that in youth with newly-diagnosed type 1 diabetes, early intensive management, including use of an automated insulin delivery system, resulted in superior Time in Range of 78% compared to 64% Time in Range in the standard-care group at one year. The CLVer Trial results were presented in a late-breaking clinical trial presentation at the ATTD Conference and concurrently published in the Journal of the American Medical Association. Innovation of technology in type 1 diabetes has transformed the therapy and significantly improved outcomes and quality of life. Data presented today at ATTD addressed one of the remaining hurdles of delivering a closed loop system - the ability to manage complex meals and exercise. Prof. Amir Tirosh, Sheba Medical Centre Israel, presented studies that evaluated simplified meal announcement approaches with the MiniMed 780G system, confirming it was able to handle unannounced meals up to 80 grams of carbohydrates, and that there was no deterioration in glycemic control when small amounts of carbs were unannounced. In addition, he presented data that precise carb counting, often seen as a prerequisite for access to advanced diabetes technology, is not as important as once thought. Meal management has been cited as one of the most challenging aspects of diabetes management as today, individuals need to calculate the number of carbs they're consuming and input it into their pump so the correct amount of insulin can be delivered. The MiniMed 780G system was designed to anticipate real life needs where carb counts aren't always exact and meal doses are often missed. As Medtronic advances its SmartGuard algorithm towards a fully closed loop system, the company is evaluating the use of its MiniMed 780G system integrated with its proprietary Klue smartwatch app which leverages hand gestures detected by a smartwatch to announce meals to the pump with the goal of eliminating manual meal announcements. Early data from a small single site study showed users were able to maintain glycemic control similar to the current standard of care of manually announcing a meal in the pump and bolusing. The study evaluated the use of the MiniMed 780G system with the Klue app disabled while traditional carb counting and carb entry were completed at baseline. Following that, the app was enabled for five days, and carb counting was prohibited. This first study of this integrated system showed that it successfully handled test meals and drinks of varying caloric and carb size while maintaining good glycemic control with a Time in Range of 80.6% during the study period.

10:22 EST Ford suspends electric F-150 production another week - Ford Motor is suspending production of its electric F-150 Lightning pickup for another week following a battery issue that resulted in one of the vehicles catching fire early this month. The company noted today that its battery supplier, SK, has started building battery cells again at a plant in Georgia but it will take time "to ensure they are back to building high-quality cells and to deliver them to the Lightning production line." It added in an emailed statement, "The teams worked quickly to identify the root cause of the issue. We agree with SK's recommended changes in their equipment and processes for SK's cell production lines."

10:01 EST Genesis Growth Tech Acquisition Corp trading resumes

10:00 EST Ambrx Biopharma falls -18.0% - Ambrx Biopharma is down -18.0%, or -$1.18 to $5.35.

10:00 EST Paymentus rises 11.9% - Paymentus is up 11.9%, or 96c to $9.02.

10:00 EST MediaAlpha rises 14.3% - MediaAlpha is up 14.3%, or $2.07 to $16.57.

09:47 EST Windtree Therapeutics Inc trading resumes

09:47 EST Ambrx Biopharma falls -15.5% - Ambrx Biopharma is down -15.5%, or -$1.01 to $5.52.

09:47 EST Paymentus rises 9.8% - Paymentus is up 9.8%, or 79c to $8.85.

09:47 EST MediaAlpha rises 16.7% - MediaAlpha is up 16.7%, or $2.42 to $16.92.

09:40 EST Genelux Corp trading resumes

09:37 EST Windtree Therapeutics Inc trading halted, volatility trading pause

09:35 EST Ocean Biomedical Inc trading resumes

09:30 EST LUNR Stock trading halted, volatility trading pause

09:17 EST Protalix, Chiesi Global receive positive CHMP opinion for pegunigalsidase alfa - Chiesi Global Rare Diseases and Protalix BioTherapeutics announced that the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion, recommending marketing authorization for PRX-102 (pegunigalsidase alfa), the first and only pegylated enzyme for the treatment of adult patients with Fabry disease. European Commission decision anticipated in beginning of May.

09:09 EST AstraZeneca completes acquisition of CinCor Pharma - AstraZeneca (AZN) announced the successful completion of the acquisition of CinCor Pharma (CINC), a U.S.-based clinical-stage biopharmaceutical company, focused on developing novel treatments for resistant and uncontrolled hypertension as well as chronic kidney disease. "The acquisition bolsters AstraZeneca's cardiorenal pipeline by adding baxdrostat, CIN-107, an aldosterone synthase inhibitor for blood pressure lowering in treatment-resistant hypertension, to its cardiorenal portfolio. Baxdrostat represents a potentially leading next-generation ASI as it is highly selective for aldosterone synthase and spares the cortisol pathway in humans1. The opportunity also brings the potential for combination with Farxiga and complements AstraZeneca's strategy to provide added benefit across cardiorenal diseases, where there is a high unmet medical need. The acquisition was completed through a tender offer to purchase all outstanding shares of CinCor for approximately $1.3bn upfront. As part of the transaction, AstraZeneca acquired the cash and marketable securities on CinCor's balance sheet, which totalled approximately $500 million as of the closing, excluding transaction-related expenses. Under the terms of the agreement, CinCor shareholders also received a non-tradable contingent value right, payable upon a specified regulatory submission of a baxdrostat product. Combined, the upfront and contingent value payments represent, if achieved, a transaction value of approximately $1.8bn. As of the expiration of the tender offer, 39,580,275 shares of CinCor were validly tendered and not validly withdrawn from the tender offer, representing approximately 86.3% of the outstanding shares of common stock of CinCor, and such shares have been accepted for payment in accordance with the terms of the tender offer. CinCor's shares will be delisted from the Nasdaq Stock Market, and CinCor will terminate its registration under the U.S. Securities Exchange Act of 1934 as soon as practicable following completion of the acquisition," the company said.

09:05 EST TrueCar forecasts 1,117,400 total new vehicle industry sales in Feb, up 5.6% y/y - TrueCar expects total new vehicle industry sales to reach 1,117,400 units in February 2023, up 5.6% from a year ago and up 4.8% from January 2023, when adjusted for the same number of selling days. This month's seasonally adjusted annualized rate for total light vehicle industry sales is an estimated 14.5M, down 3.8% from February 2022. Excluding fleet sales, TrueCar expects U.S. retail deliveries of new cars and light trucks to be 928,386 units, up 1% from a year ago and up almost 3% from January 2023.

09:03 EST LiveOne named marketing, content partner for 50th Anniversary of Hip Hop team - The 50th Anniversary of Hip Hop team of Legends Recordings, Beats Rhymes and Relief and The Brand Liaison has named LiveOne as the Marketing and Content Partner for their upcoming three-day celebration of Black excellence, culture and the 50th Anniversary of Hip Hop. Taking place at City Point, located at 445 Albee Square West in Brooklyn, New York, from February 24th - 26th, the programming will include art, cultural events and live music performances.

09:00 EST Oxus Acquisition Corp trading resumes

08:47 EST Falco Resources extends certain deadlines under silver stream transaction - Falco Resources (FPRGF) and Osisko Gold Royalties (OR) have entered into an amendment to the silver stream agreement dated February 27, 2019 relating to Falco's Horne 5 Project. The amendment postpones to January 31, 2025 the deadlines granted to Falco to achieve milestones set as conditions precedent to Osisko funding the second and third instalments of the stream deposit, which instalments would be funded concurrently if such conditions are satisfied. The independent directors of the Corporation have approved such amendments under the silver stream agreement.

08:42 EST 1847 Holdings COO Eric VanDam resigns - 1847 Holdings announced that it has appointed Glyn Milburn as Vice President of Operations. Additionally, the Company announced that Eric VanDam resigned from his position as COO to pursue an opportunity closer to where he resides in Michigan and not due to any disagreement with the Company on any matter relating to the Company's operations, policies or practices.Mr. Milburn has been a member of 1847's board of directors since August 2022. Since January 2021, Mr. Milburn has served as a Director at Ygrene Energy Fund,

08:41 EST Cornerstone completes merger with SolGold - Cornerstone Capital Resources announced the completion of the plan of arrangement with SolGold effective February 24, 2023. Cornerstone is now a wholly-owned subsidiary of SolGold. In connection with the Arrangement, SolGold acquired all of the issued and outstanding common shares of Cornerstone, other than the Cornerstone Shares already held, directly or indirectly, by SolGold. In particular, holders of Cornerstone Shares, other than SolGold, received 15 SolGold ordinary shares for each Cornerstone Share held. The SolGold Shares that were issued pursuant to the Arrangement have been admitted to the standard listing segment of the Official List of the UK Financial Conduct Authority and have been admitted for listing and trading on the Main Market of the London Stock Exchange and the Toronto Stock Exchange under the symbol "SOLG", subject only to the satisfaction of customary listing conditions. The Cornerstone Shares are expected to be de-listed from the TSX Venture Exchange after the close of trading on February 28, 2023. It is also expected that the Cornerstone Shares will cease trading on the OTC Pink Market and Frankfurt Stock Exchange. SolGold will cause Cornerstone to apply to the relevant Canadian securities regulatory authorities to cease to be a reporting issuer under applicable Canadian securities laws.

08:39 EST Sono Group announces COO Hausch to step down - In light of the Company's decision to terminate the Sion program, the Company plans the redundancy of approximately 300 employees. In this context, Thomas Hausch has decided to step down from his role as COO but will support the Company's transition.

08:39 EST Runway Growth declares dividend of 40c per share with 5c supplemental dividend - Runway Growth Finance Corp. (Nasdaq: RWAY) ("Runway Growth"), a leading provider of flexible capital solutions to late- and growth-stage companies seeking an alternative to raising equity, today announced that its Board of Directors has declared a first quarter 2023 cash distribution of $0.40 per share. This dividend represents an increase of 11% over the base dividend declared in the prior quarter; and the fifth consecutive quarter of dividend increases since becoming a listed company. In addition, the Board of Directors declared a supplemental dividend of $0.05 per share, for the first quarter of 2023. Runway Growth intends to declare and pay a similar supplemental dividend for each subsequent fiscal quarter during 2023, subject to future approval by the Board of Directors. The following shows the key dates of the first quarter 2023 dividend, including the supplemental dividend: Declaration Date: February 23, 2023; Record Date: March 7, 2023; Payment Date: March 21, 2023.

08:34 EST MICT, Inc. announces rebranding, name change to Tingo Group - MICT (MICT) announced that it is changing its name to Tingo Group, Inc. effective prior to the market open on Monday, February 27, 2023. The ticker symbol "MICT" will change to "TIO" and the stock will continue to trade on the Nasdaq Capital Market. Darren Mercer, Chief Executive Officer of MICT, commented: "The Tingo brand is extremely important to the business, not only as Africa's leading agri-fintech solution, but also as a Pan-Africa fintech partner to Visa, through TingoPay, and in connection with the recently launched businesses of Tingo Foods and the Tingo DMCC commodities platform and export business. The Company's change of name reflects this and also provides improved clarity to our external stakeholders, including current and prospective partners, customers, and investors. "The Company is in the process of pivoting its insurance and financial services businesses to compliment the Tingo brand and leverage Tingo's fast growing customer base through the addition of new products with significant new income streams. Taking this into account, together with the expected considerable growth in consolidated group revenues and profitability in 2023 and beyond, we believe it is important to unify the Company through a single corporate identity reflected through a single global brand."

08:22 EST WM Argyle Fund calls Broadwind loan default 'indefensible for management' - WM Argyle Fund, an investment fund which recently announced its nomination of six independent director candidates to the Board of Directors of Broadwind, commented on a Form 8-K filed by the Company with the Securities and Exchange Commission on February 14th, 2023. In the Form 8-K, the Company disclosed that it amended a Credit Agreement after failing to meet the lender's minimum EBITDA threshold of $2.5M for the twelve month period ended December 31, 2022, which created an event of default under the Credit Agreement. The Fund said, "The filing indicates the Company's EBITDA projections in August, when it entered into the Credit Agreement, did not last four months. We find it hard to believe the Company would knowingly agree to debt covenants it could not meet, which therefore suggests its projected financial performance declined in Q4. We find the loan default and the reductions in Q1 and Q2 2023 quarterly EBITDA covenants in the amended loan agreement to be indefensible for management and the Board. We are asking that management and the Board publicly explain to stockholders how this happened and what they are planning to do to address the causes for this default. Getting loan waivers is only a bandage to cover the much greater wound the Company is facing in credibility with lenders and shareholders. We hope last week's filing is not a prelude to reporting further declines in its Q4 operating performance or future guidance. Broadwind has great potential, but stockholders deserve a board that will hold management accountable for its repeated failure to achieve growth and profitability."

08:17 EST BASF to cut 2,600 jobs to save costs in Europe - In his presentation of results, Chairman Martin Brudermuller announced cost savings measures focused on Europe as well as measures to adapt the production structures at the Verbund site in Ludwigshafen. The cost savings program, which will be implemented in 2023 and 2024, focuses on rightsizing BASF's cost structures in Europe, and particularly in Germany, to reflect the changed framework conditions. On completion, the program is expected to generate annual cost savings of more than EUR 500 million in non-production areas, that is in service, operating and research & development divisions as well as the corporate center. Roughly half of the cost savings are expected to be realized at the Ludwigshafen site. The measures under the program include the consistent bundling of services in hubs, simplifying structures in divisional management, the rightsizing of business services as well as increasing the efficiency of R&D activities. Globally, the measures are expected to have a net effect on around 2,600 positions; this figure includes the creation of new positions, in particular in hubs. Reference Link

08:09 EST SeaStar Medical's SCD to be featured at CKD5 - SeaStar Medical Holding Corporation announces that Kevin Chung, M.D., Chief Medical Officer, will discuss the Company's Selective Cytopheretic Device, SCD, in a presentation at the 5th Chronic Kidney Disease Drug Development Summit, CKD5, in Boston on March 7, 2023 at 10 a.m. Eastern Time. In his presentation, "The Selective Cytopheretic Device: A Novel Host Response Targeting Cell-Directed Extracorporeal Therapy in AKI," Dr. Chung will discuss the impact of systemic inflammation as a key driver of organ dysfunction and damage in the setting of acute and chronic diseases such as AKI and chronic kidney disease. He will detail the advantages of targeting leukocytes - the main function of the SCD - over targeting downstream byproducts of hyperinflammation. Dr. Chung will also review the clinical data from studies with the SCD in adult and pediatric patients with AKI and COVID-19.

08:06 EST Emcor raises quarterly dividend to 18c from 15c per share - In yesterday's announcement, Emcor board announced it expects to declare this cash dividend starting in the second quarter of 2023.

08:05 EST Chembio Diagnostics announce receipt of CLIA waiver for DPP HIV-Syphilis system - Chembio Diagnostics announced receipt of a Clinical Laboratory Improvement Amendments, CLIA, waiver from the U.S. Food and Drug Administration, FDA, for the DPP HIV-Syphilis System. "The DPP HIV-Syphilis System represents an exciting advancement in rapid testing for sexually transmitted infections. We are excited that the 200,000+ CLIA waived point-of-care testing sites in the U.S. now have access to the DPP HIV-Syphilis System where its use can help save lives and minimize the spread of both HIV and syphilis," said Richard Eberly, Chembio's President and CEO. "Rapid HIV and syphilis combination testing is now even more important to community health as the U.S. Centers for Disease Control and Prevention's most recent sexually transmitted disease surveillance data reports that STDs in the U.S. have reached all-time highs for the sixth consecutive year. Most importantly, the DPP HIV-Syphilis System offers actionable information to better manage two of the most critical threats posed by syphilis infections: the potentially lethal mother to child transmission and the increased risk of contracting HIV." Chembio's DPP HIV-Syphilis System assists clinicians in diagnosing both HIV and syphilis while patients are still under care at the testing location. The DPP HIV-Syphilis System is a multiplex, single-use, 15-minute test that is designed, in combination with Chembio's Micro Reader analyzer, to simultaneously detect antibodies to HIV types 1 and 2 and Treponema pallidum, the bacteria that causes syphilis.

08:03 EST Par Pacific announces expiration, results for cash tender offers - Par Pacific Holdings announced the expiration and results of the previously announced cash tender offers by Par Petroleum to purchase any and all of the approximately $281,000,000 outstanding aggregate principal amount of the 7.750% Senior Secured Notes due 2025 issued by the Company and Par Petroleum Finance Corp., and any and all of the approximately $31,314,000 outstanding aggregate principal amount of the Issuers' 12.875% Senior Secured Notes due 2026, with a portion of the net proceeds from the Issuers' proposed entry into a private senior secured term loan B due 2030. The tender offers expired at 5:00 p.m., New York City time, on February 23, 2023. As of the Expiration Time, an aggregate principal amount of $260,587,000, or approximately 92.74%, of the 2025 Notes and $29,038,000, or approximately 92.73%, of the 2026 Notes were validly tendered and not validly withdrawn. In addition, $270,000 aggregate principal amount of the 2025 Notes were tendered subject to guaranteed delivery procedures. Subject to raising at least $550 million in gross proceeds from the proposed private senior secured term loan B due 2030, the Company expects to accept for payment all Notes validly tendered prior to the Expiration Time pursuant to the offer to purchase and all Notes properly delivered under guaranteed delivery procedures and expects to make payment for all such Notes on February 28, 2023.

08:02 EST Windtree Therapeutics issued new istaroxime patent from USPTO - Windtree Therapeutics announced that the United States Patent and Trademark Office, USPTO, has issued U.S. Patent No. 11,583,540, providing expanded patent coverage for istaroxime administration. The new U.S. patent, titled: "Istaroxime-Containing Intravenous Formulation for the Treatment of Acute Heart Failure", is a continuing patent following the expedited U.S. Track One filing by Windtree, which resulted in U.S. Patent No. 11,197,869 that issued December 14, 2021. The claims of the newly issued patent cover longer durations of istaroxime infusion for improved outcomes in treatment of acute heart failure. In particular, the claims are directed to an improvement in diastolic heart function following administration of istaroxime by intravenous infusion for 6 hours or more, which Windtree attributes to the SERCA2a mechanism of action of istaroxime and its metabolites. "Windtree continues to strengthen the patent estate for istaroxime with this new issuance from the USPTO," said Craig Fraser, CEO and President of Windtree Therapeutics. "We believe istaroxime is differentiated from other drugs that are used to treat acute decompensated heart failure and this patent provides additional rationale for how it can provide unique benefits to potential patients. We plan to continue this work to further expand istaroxime's patent estate in the clinical development work ahead."

08:01 EST Fulcrum Therapeutics announces clinical hold on FTX-6058 in SCD - Fulcrum Therapeutics announced that on February 23, 2023, the U.S. Food and Drug Administration verbally informed the company that it has issued a full clinical hold regarding the Investigational New Drug application for FTX-6058 for the potential treatment of sickle-cell disease. The Agency indicated that it would provide a formal Clinical Hold Letter to the company within 30 days. The clinical hold was initiated by the Agency due to previously reported preclinical data. Fulcrum will suspend dosing in the Phase 1b trial of FTX-6058 and intends to work diligently with the Agency to resolve the hold as soon as possible.

07:58 EST BASF terminates share buyback program ahead of schedule - In line with the company's priorities for the use of cash and in view of the profound changes in the global economy in the course of 2022, the Board of Executive Directors of BASF SE has decided to terminate the share buyback program ahead of schedule. On January 11, 2022, BASF SE disclosed pursuant to art. 5 para. 1 lit. of the Regulation no. 596/2014 and art. 2 para. 1 of the Delegated Regulation no. 2016/1052 the start of the share buyback on January 11, 2022. The share buyback program was intended to reach a volume of up to EUR 3 billion and be concluded by December 31, 2023, at the latest. The volume of shares which have been bought back within the framework of the share buyback program in the period from January 11, 2022, until and including February 17, 2023, amounts to a number of 25,804,062 shares; this corresponds to 2.8 percent of the share capital on announcement of the program. The purchase price for these own shares totaled around EUR 1.4 billion. The purchase of the shares was carried out by the banks that had been commissioned by BASF SE via the electronic trading platform of the Frankfurt Stock Exchange Reference Link

07:46 EST Jacobs awarded $3.2B contract at NASA Kennedy Space Center - Jacobs was awarded the Consolidated Operations, Management, Engineering & Test contract at NASA Kennedy Space Center. The contract is estimated at approximately $3.2B over 10 years and extends Jacobs' role managing KSC's launch infrastructure as well as ground processing for NASA programs, including the Exploration Ground Systems program, International Space Station program and other key NASA spaceflight programs dating back to 2013. Under the contract, Jacobs will provide engineering; ground system development; flight vehicle/spacecraft processing; and launch, landing and recovery operations for NASA's major Exploration Systems Development programs: Exploration Ground Systems, Space Launch System and Orion programs.

07:38 EST T-Mobile announces equity investment in Movius - T-Mobile announced an equity investment through T-Mobile Ventures in Movius, a software provider for secure and compliant mobile communications. The investment reflects the benefits that businesses and other organizations are seeing with T-Mobile MultiLine, which is powered by Movius. MultiLine allows employees to use a single smartphone for personal and business communications in a way that meets compliance standards. It enables employees to use their personal phone to call, text and even use apps like WhatsApp on a dedicated, secure, compliant business line. T-Mobile MultiLine is currently in use by businesses of all sizes in many industries, including many tier one global banks.

07:36 EST Zevra announces arimoclomol featured in two poster presentations - Zevra Therapeutics announced that arimoclomol, the Company's investigational product candidate being developed as a treatment for Niemann-Pick disease type C, is being featured in two poster presentations during the 19th Annual WORLDSymposiu 2023, the annual research conference dedicated to lysosomal diseases being held February 22-26, 2023 in Orlando, Florida, USA. Research presented at WORLDSymposium 2023 included an interim analysis from the ongoing four-year open-label extension of the Phase 2/3 clinical trial of arimoclomol. Results from this analysis, based on up to four years of continuous treatment, suggest that arimoclomol may reduce the long-term progression of NPC. Zevra plans to include these data as part of the updated New Drug Application for arimoclomol, which the Company expects to resubmit to the U.S. Food and Drug Administration as early as the third quarter of 2023. The first poster, titled, "Evaluation of the Long-Term Effect of Arimoclomol in NPC," reported 48-month data from the open-label extension of the Phase 2/3 clinical trial of arimoclomol in NPC. Upon fulfilling the randomized double-blinded portion of the phase 2/3 clinical trial, both placebo- and arimoclomol-treated patients were given the option to continue into the four-year OLE phase of the study with arimoclomol treatment provided in addition to their current standard of care. Progression of NPC disease through the DB and OLE phases was assessed utilizing the five-domain NPC Clinical Severity Scale and compared with an estimated progression calculated from the combination of untreated patients from the NPC-001 observational trial and placebo patients from the NPC-002 Phase 2/3 trial. The second poster titled, "Association Between NPC Severity Score Domains and Corresponding Items of the Performance-based Scale for the Assessment and Rating of Ataxia, SARA," reported research investigating correlations between relevant 5DNPCCSS domains and corresponding SARA test items to potentially provide further supportive evidence for 5DNPCCSS validity as a tool for evaluating NPC progression. Based on a comparative analysis of both measurements, it was determined that individual 5DNPCCSS domains and relevant performance-based SARA test items showed strong associations and alignment between the two instruments for all analysis methods used.

07:34 EST CRC CEO Mark McFarland to switch roles, Francisco Leon to succeed - California Resources announced a strategic realignment of the company's business operations and structure. The company intends to reduce costs to align with activity levels, increase its financial flexibility and optimize its portfolio of assets. The company believes that the combination of these actions will allow it to continue to strengthen shareholder returns. The company is also repositioning the business to capitalize on future opportunities with Carbon TerraVault. In conjunction with this strategic realignment, the company also announced that Francisco Leon, currently CFO, will succeed Mark McFarland as president and CEO and join the company's board of directors, effective at the company's 2023 annual meeting in April. With the revised corporate structure, Leon will assume the CEO position, effective at the company's annual meeting. In May, McFarland will transition to his former role as a non-executive director and will also serve as non-executive chair of the newly formed board of the Carbon TerraVault subsidiary. Two existing CRC non-executive directors, Andrew Bremner and James Chapman, will also serve on that subsidiary board. The company has an ongoing search for a new CFO. The company will reduce its rig count to 1.5 in 2023 with a drilling program focused on developing the highest-returning projects with permits-in-hand in conjunction with a continued focus on well servicing and downhole maintenance to reduce the base production decline to approximately 5% to 7%. At the planned rig pace, CRC can enhance the operational and capital efficiency of its rig program and maximize the company's ability to return capital to shareholders. On a go-forward basis utilizing a 1.5 rig program, CRC expects to spend $155M in E&P drilling and completions and workover capital. This level of spending excludes one-time items and CMB capital which is anticipated to be funded by projected CTV JV contributions over time. CRC's leadership team, working closely with the Special Finance Committee is focused on cost reduction initiatives across the company that align with the projected level of activity and revised strategic direction. CRC is targeting a 5%-10% reduction in non- energy operating costs and adjusted E&P Corp & Other G&A1 on a combined basis by year end. These cost reduction initiatives in conjunction with increased downhole maintenance target maintaining margins and driving higher cash flows. CRC's leadership team and board have successfully implemented similar strategies and believe the company is well positioned to identify and achieve cost reductions while maintaining the high operational standards that CRC has achieved. In addition, CRC will continue to pursue the monetization of its Huntington Beach surface acreage as well as other real estate surface ownership in its portfolio. CRC intends to optimize capital allocation and focus on cost reduction opportunities in 2023 to drive cash flow generation that it believes will allow it to increase shareholder returns. To that end, CRC's board has authorized a nearly 30% increase to its shareholder repurchase program for a total of $1.1B, with $640M remaining on its authorization as of December 31, 2022, and after taking account the increase. In 2023, CRC is positioning to return approximately 100% of free cash flow through buybacks and dividends.

07:32 EST Werewolf Therapeutics doses first patient in Phase 1 study of WTX-330 - Werewolf Therapeutics announced that the first patient has been dosed in a Phase 1 clinical trial evaluating WTX-330, the Company's lead INDUKINETM molecule targeting Interleukin-12, IL-12. "Dosing the first patient in our Phase 1 trial of WTX-330 marks the second INDUKINE molecule arising from our PREDATORTM protein engineering platform to enter the clinic. Our continued transition into a clinical stage company comes at an exciting time for Werewolf following the initiation of a Phase 1/1b clinical study of WTX-124 last year," said Daniel Hicklin, Ph.D., Werewolf's Founder and Chief Executive Officer. "WTX-330 serves as another example of our team's capacity to expand our clinical pipeline and validates our novel approach of developing conditionally activated cytokines as cancer therapies to improve outcomes for patients with hard-to-treat tumors."

07:32 EST E.W. Scripps sees Q1 local media revenue down mid-single-digits vs. last year

07:20 EST BeiGene announces China NMPA approval for tislelizumab - BeiGene announced that the China National Medical Products Administration, or NMPA, granted approval for the company's PD-1 inhibitor, tislelizumab, in combination with fluoropyrimidine and platinum chemotherapy, for the first-line treatment of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma with high PD-L1 expression.

07:17 EST Passage Bio presents additional interim data from Imagine-1 study - Passage Bio announced updated clinical data from Imagine-1, a Phase 1/2 study of PBGM01, a gene therapy for GM1 gangliosidosis, are being presented today at the 19th Annual WORLDSymposium. Imagine-1 is a global, open-label, dose-escalation study of the AAVhu68 gene therapy PBGM01 delivered by intra-cisterna magna injection in four cohorts of pediatric subjects with early and late infantile GM1 Gangliosidosis. "We are pleased to share promising data from the first six patients in our Imagine-1 study that continue to demonstrate PBGM01 has exerted a biological effect in patients with infantile forms of GM1 gangliosidosis," said William Chou, M.D., chief executive officer of Passage Bio. "At this interim analysis, all treated patients showed stabilization of MRI severity scores, a potential marker of disease severity and progression measured by structural damage of the brain. Furthermore, patients exhibited decreases in urine levels of the beta-Gal substrate Dp5, an exploratory biomarker of peripheral beta-Gal activity. These data are supported by the favorable safety profile of PBGM01 and bolster our confidence in PBGM01 as a potential treatment option for GM1 patients. We look forward to continued advancement of our Imagine-1 study and sharing new data from Cohort 4 by mid-year."

07:16 EST Brady provides recast historical data for new operating segments - Brady Corporation is providing recast historical financial data for fiscal 2021, 2022 and the first two quarters of fiscal 2023 for its new operating segments announced on December 1, 2022, which are effective in the Company's third quarter of fiscal 2023. The Company has recast its historical financial data to disclose sales and segment profit for its two new operating segments: Americas & Asia and Europe & Australia. This change to a regional operating structure will allow the Company to further integrate its businesses, support continued growth through the application of its best go-to-market strategies in key geographies, facilitate new product development in its recent acquisitions and further simplify its global business. The Company expects that the change to a regional structure will result in an improvement of approximately $0.10 to $0.20 of Earnings per diluted Class A Common Share beginning primarily in fiscal 2024. One-time charges resulting from employee severance are expected to be largely offset by reduced costs in fiscal 2023.

07:12 EST Verano Holdings opens MUV West Palm Beach Okeechobee - Verano Holdings announced the opening of MUV West Palm Beach Okeechobee on Friday, February 24; this is the Company's 65th Florida dispensary and 124th retail outlet nationwide. MUV West Palm Beach Okeechobee, located at 2550 Okeechobee Boulevard, is open Monday through Saturday from 9 a.m. to 7 p.m. and Sunday from 11 a.m. to 5 p.m., local time.

07:07 EST ObsEva announces delisting from Nasdaq Capital Market - ObsEva has also notified The Nasdaq Stock Market of the Company's inability to comply with Listing Rule 5450(a)(1) because the bid price of ObsEva's common shares was not at least $1.00 per share for ten consecutive business days since receiving the non-compliance notice on September 12, 2022. ObsEva had until March 13, 2023 to regain compliance with the minimum bid price requirement. Upon delisting of ObsEva's common shares from the Nasdaq Capital Market, the Company intends to deregister with the SEC to suspend its obligation to file periodic reports under the Securities Exchange Act of 1934, as amended, including annual, quarterly and current reports on Form 10-K, Form 10-Q and Form 8-K, respectively, once certain conditions to deregistration are satisfied, including the Company having fewer than 300 record holders of its common shares. The Company expects the Nasdaq delisting and SEC deregistration to contribute to lower general and administrative costs in the future. ObsEva intends to maintain its SIX Swiss Exchange listing and to continue to trade under the ticker symbol OBSN.

07:05 EST Cato Corp. announces 1M share increase to share repurchase plan - The company announced that its Board of Directors has authorized a 1M share increase in the company's share repurchase program. Prior to this authorization, the company had approximately 135,000 shares remaining in open authorizations.

07:04 EST ObsEva announces sreorganization to consolidate operations in Switzerland - ObsEva announced a strategic reorganization that will consolidate operations in Switzerland so as to preserve cash, focus resources towards the development of nolasiban, a novel, oral oxytocin receptor agonist to improve in vitro fertilization success rates, and manage its out-licensed programs. As part of the reorganization, the Company is downsizing its US-based Executive Management team and will similarly propose a reduced Board of Directors at the next Annual General Meeting. Additionally, ObsEva is retiring its convertible debt, is expecting to be delisted from Nasdaq, and intends to deregister from the US Securities and Exchange Commission while maintaining its current listing on SIX Swiss Exchange. In connection with the reorganization, ObsEva's Chairwoman, Annette Clancy, and Board members Brian O'Callaghan, Stephanie Brown, Anne VanLent, and Ed Mathers will not stand for re-election at the Company's upcoming annual general meeting of shareholders. It is intended that ObsEva's Founder, Dr. Ernest Loumaye, will be nominated as Board Chairman along with the nomination of Catarina Edfjall as Board member. Brian O'Callaghan stepped down as Chief Executive Officer effective February 23, 2023, with Will Brown, current Chief Financial Officer, appointed as Interim Chief Executive Officer, while also retaining the title of Chief Financial Officer. Additionally, Clive Bertram, Chief Commercial Officer, Brandi Howard, Chief Clinical Officer, and Luigi Marro, Chief Transformation Officer also departed the Company effective February 23, 2023. The Company has initiated a search for a permanent Chief Executive Officer to be based in Geneva, Switzerland. The reorganization is expected to provide annual compensation savings of approximately $3.5 million. ObsEva has also negotiated the early retirement of $6.5 million in debt that represent amounts owed to certain funds and accounts managed by JGB Management pursuant to the Company's Securities Purchase Agreement with JGB. Under the terms of the early retirement, ObsEva and JGB agreed to apply $6.5 million previously held as collateral in a control account against the outstanding convertible notes on a pro rata basis, with JGB waiving a $1.1 million prepayment penalty in exchange for approximately $566 thousand in cash and $250,000 in the form of approximately 1.5 million common shares.

06:51 EST Merck, Ridgeback: CHMP of EMA recommends refusal of MAA for lagevrio - Merck and Ridgeback Biotherapeutics announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended the refusal of the marketing authorization for lagevrio for the treatment of certain adults who have been diagnosed with COVID-19 in the European Union. Merck and Ridgeback will appeal the decision and request a re-examination of the CHMP's opinion.

06:43 EST SEC says Elon Musk still needs lawyer to approve tweets - In a letter to the U.S. Court of Appeals for the 2nd Circuit in New York, the U.S. Securities and Exchange Commission said Tesla CEO Elon Musk still needs to get pre-approval from lawyers prior to tweeting Tesla-related information. Earlier this week, Musk's lawyers contended a recent jury verdict in a private securities-fraud action should be considered in the appeal of the SEC settlement provision, however the agency said the verdict doesn't qualify as a "pertinent and significant" authority and Musk "waived his opportunity to test the Commission's allegations at trial when he voluntarily agreed (twice) to a consent judgement." Reference Link

06:38 EST HF Sinclair raises quarterly dividend to 45c from 40c per share - The dividend is payable on March 17 to holders of record of common stock on March 7.

06:28 EST U.S. Silica sees FY23 capital expenditures $50M-$60M - The company said, "Looking forward to the first quarter and into 2023, the Company's two business segments remain well positioned in their respective markets. The Company has a strong portfolio of industrial and specialty products that serve numerous essential, high growth and attractive end markets, supported by a robust pipeline of new products under development. The Company also expects growth in its underlying base business, coupled with pricing increases and surcharges to continue to fight inflationary impacts. The oil and gas industry is progressing through a multi-year growth cycle. Constructive customer sentiment and strength in WTI crude oil prices are supportive of an active well completions environment in 2023. The Company remains focused on generating free cash flow and de-levering the balance sheet and intends on being operating cash flow positive in 2023, keeping an estimated $50-$60 million of capital expenditures within operating cash flow."

05:11 EST HP Enterprise acquires Athonet, terms undisclosed - HP Enterprise announced the expansion of its connected edge-to-cloud offering with the acquisition of Athonet, a private cellular network technology provider that delivers mobile core networks to enterprises and communication service providers. Combined with the HPE telco and Aruba networking portfolios, Athonet will put HPE at the forefront of a growing market that is predicted by IDC to increase to more than $1.6B by 2026. Based in Vicenza, Italy, Athonet has more than 15 years of experience delivering 4G and 5G mobile core solutions to customers and partners globally. Athonet has more than 450 successful customer deployments in various industries, including mobile operators, hospitals, airports, transportation ports, utilities, government and public safety organizations. HPE will integrate Athonet's solutions with its existing telco software assets and plans to make them available to customers some time following the close of the transaction. HPE will also integrate the solutions with the Aruba networking portfolio in the near future. The transaction is expected to close at the beginning of the third quarter of HPE's 2023 fiscal year, subject to regulatory approvals and other customary closing conditions.